Project Grant R01AI182098
Award Date
5/1/25
Completion Date
4/30/30
Dollars Obligated
$858K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award of $547,945.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to investigate the pathogenesis of immune checkpoint inhibitor (ICI)-induced myocarditis at The Johns Hopkins University. The key objectives are to: Examine how biological factors such as prior cardiac injury, age, and sex influence the risk and severity of ICI-myocarditis by modulating autoreactive, tissue-resident memory T (TRM) cells specific to cardiac...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $117,804 to The Leland Stanford Junior University to investigate the role of macrophages and CXCR3+ T-cells in immune checkpoint inhibitor (ICI)-induced myocarditis. The research aims to elucidate how CXCL9/10-expressing macrophages contribute to the recruitment of CXCR3+ effector...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), is funding a comprehensive research effort to investigate the genetic factors associated with immune-related adverse events (irAEs) in cancer patients receiving immune checkpoint inhibitor (ICI) treatments. The $689,934 award to the Dana-Farber Cancer Institute (DFCI) aims to conduct the largest genome-wide association study (GWAS) on irAEs, analyzing data from...
The Department of the Army Medical Command awarded a $695,089 Project Grant to the Dana-Farber Cancer Institute, Inc. under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from June 1, 2022 to May 31, 2025 to develop noninvasive diagnosis of immune checkpoint inhibitor-associated myocarditis. The Military Medical Research and Development program supports biomedical research that transforms military and public health care through innovative...
The federal Project Grant award R01CA294793, totaling $701,408.00, was provided by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395). The funding supports a research initiative at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to elucidate resistance mechanisms and enhance response to immune checkpoint blockade in central nervous system metastases from breast cancer. The project involves conducting...
This $167,864 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) will support a comprehensive investigation of risk stratification and outcomes across the full spectrum of cardiotoxicity from immune checkpoint inhibitor (ICI) cancer therapies. The study aims to (1) retrospectively examine cardiac and oncologic outcomes associated with ICI cardiotoxicity based on patient symptoms and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $500,000 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on modulating T cell activation to combat HIV persistence. The 5-year project, starting on September 1, 2024, aims to identify and perturb regulatory mechanisms governing antigen-refractory HIV-specific CD8+ T...
This Project Grant award of $711,704.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Mayo Clinic supports research to understand the determinants of severe immune-related adverse events (IRAEs) in melanoma patients treated with combination immune checkpoint inhibitor therapies. The research aims to: Determine if levels of peripheral helper T (Tph) cells in pre-treatment blood can predict development of severe IRAEs in melanoma patients receiving combination...
This Project Grant award, with a total funding amount of $196,029, is provided by the National Cancer Institute (NCI) under the Cancer Research Manpower federal grant program (CFDA 93.398). The grant supports research conducted by the University of Massachusetts Medical School to decipher the immune evasion mechanisms in cancers harboring mutations in the isocitrate dehydrogenase 1 (mIDH1) gene. The research aims to elucidate two key processes: 1) the role of viral mimicry in the response to...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1,074,434.37 Project Grant to the Massachusetts General Hospital under the Allergy and Infectious Diseases Research program (CFDA 93.855) on March 17, 2021 with a completion date of July 12, 2021. The grant funding supports research to develop protocols to induce tolerance in non-human primate heart allograft recipients without chronic immunosuppression. The awardee will test approaches to either...